Whole-genome sequencing (WGS) data from all non-overlapping studies were exported to NSCLC cBioPortal (available at http://www.cbioportal.org (accessed on 21 April 2025)), and it was determined that ERBB2 mutations occur in 3.5% of NSCLC cases (Figure 2). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.